Patients & Caregivers

Clinical Trials

Advancing Multiple Global Clinical Trials for Obexelimab to Treat Autoimmune Diseases

• Immunoglobulin G4-Related Disease (IgG4-RD)

  Trial Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With IgG4-Related Disease (INDIGO) Trial Number: NCT05662241 Stage: Phase 3 Status: Target Enrollment Complete

• Multiple Sclerosis (MS)

  Trial Title: A Phase 2 double-blinded, randomized, placebo-controlled study assessing efficacy and safety of obexelimab, in patients with Relapsing Multiple Sclerosis (MoonStone) Trial Number: NCT06564311 Stage: Phase 2 Status: Enrolling

• Systemic Lupus Erythematosus (SLE)

  Trial Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Systemic Lupus Erythematosus (SunStone) Trial Number: NCT06559163 Stage: Phase 2 Status: Enrolling

• Warm Autoimmune Hemolytic Anemia (wAIHA)

  Trial Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label Safety and Dose Confirmation Run-In Period, To Evaluate the Efficacy and Safety of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) Trial Number: NCT05786573 Stage: Phase 2/3 Status: Enrolling

Learn more about your eligibility for these clinical trials by visiting https://indigo.patientwing.com (IgG4-RD) and https://saphiare.patientwing.com (wAIHA).